NCT07101705 - An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions

Multiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL)

Interventions

DRUG

OriV508 Injection

OriV508 injection is one kind of non-replicative self-inactivating lentivirus vector which carries an effective BCMA/CD19 dual-target CAR. OriV508 can be administered intravenously and produce BCMA/CD19 CAR-T in vivo.

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan